ARTICLE | Emerging Company Profile
Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal
Cell Design Lab successor Kyverna aims to expand T cell therapies to autoimmune diseases
January 14, 2020 12:13 AM UTC
Updated on Jan 14, 2020 at 12:38 AM UTC
The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is applying a set of T cell therapy technologies to autoimmune diseases, lending more support to the notion that T cell therapies have benefits beyond cancer.
Kyverna Therapeutics Inc. came out of stealth on Monday with a $25 million series A round from founding investors Vida Ventures and Westlake Village BioPartners, as well as Gilead Sciences Inc. (NASDAQ:GILD). ...